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Abstract
Purpose We evaluated the use of logistic regression to
model the probabilities of spontaneously reported vaccine–
event pairs being adverse reactions following immuniza-
tion (ARFI), using disproportionality and unexpectedness
of time-to-onset (TTO) distributions as predictive variables
and the presence of events in the global product informa-
tion as a dependent variable.
Methods We used spontaneous reports of adverse events
from eight vaccines and their labels as proxies for ARFIs.
Three logistic regressions were built to predict ARFIs
based on different combinations of the proportional
reporting ratio (PRR; disproportionality measure) and two
Kolmogorov–Smirnov (KS) tests (‘between vaccines’ and
the ‘between events’) of TTO distribution: model 1, using
the PRR estimate and its 95 % lower confidence interval
(CI) limit; model 2, using the p values of the two KS tests;
and model 3, using the PRR (point estimate and lower CI
limit) and both KS tests. The performance of the regres-
sions (model fit statistics, calibration, and discrimination)
was measured on 100 bootstrap samples.
Results Model 3, using two quantified causality criteria,
provided the best performance for all measures. The
p value of the ‘between vaccines’ KS test was the most
significant predictive factor. Model 1 had the worst
performance.
Conclusions Logistic regression allows estimation of the
probability of a vaccine–event pair being an ARFI using
two causality criteria at the population level assessed in
spontaneous report data: the strength of association (dis-
proportionality measure) and temporality (TTO distribution
tests). Logistic regression combines and weights these
causality criteria based on their respective ability to predict
known safety issues.
Key points
The performance of three logistic regression
models, incorporating different combinations of
quantified causality criteria, was evaluated for the
detection of safety signals from vaccine
spontaneous report data
The logistic regression model integrating only the
measure of the strength of association appeared to
have the lowest performance for predicting known
safety issues
The unexpectedness of the time-to-onset
distribution for a given vaccine–event pair (when
compared with the time-to-onset distribution of
the same event reported following exposure to
other vaccines) appeared to be best predictor of
the reported event being a known safety issue
Logistic regression offers a framework in which
quantified causality criteria can be combined to
evaluate the probability of a vaccine–event pair
being an adverse reaction following immunization
based on our existing knowledge of vaccine safety
profiles
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1 Introduction
Data mining algorithms (DMAs) have been developed for
screening spontaneous report databases (SRDs). The
majority of these algorithms detect product–event pairs (P–
Es) presenting a disproportionate number of reports com-
pared with the expected number from other/all products
and other/all events within the same SRD [1, 2]. This
measure of disproportionality offers a proxy of the strength
of association between a product and an event while
accounting for the absence of exposure data characteristics
of spontaneous data [3].
These DMAs were first developed for screening the
SRDs held by regulatory authorities: the Empirical Bayes
Geometric Mean (EBGM) for the Food and Drug Admin-
istration SRD [2], the information component (IC) for the
World Health Organization (WHO) SRD, the proportional
reporting ratio (PRR) for the UK SRD, and the reporting
odds ratio for the Netherlands Pharmacovigilance Foun-
dation Lareb SRD. Over time, the use of these DMAs
extended to SRDs held by drug and vaccine manufacturers.
In this study, we focus on the GlaxoSmithKline (GSK)
vaccines SRD containing spontaneously reported adverse
events (AEs) following immunization by a GSK vaccine.
These DMAs all share the same objective: to estimate
the strength of association. However, this is only one of a
number of causality criteria at the population level for
determining whether a vaccine may have caused a partic-
ular AE (others include temporal relationship, dose-
response relationship, consistency of evidence, specificity,
biological plausibility, and coherence) [4]. The use of the
causality criterion strength of association does not neces-
sarily require prior medical insight or external data sources.
DMAs have thus focused only on strength of association,
allowing signals of disproportionate reporting to be gen-
erated autonomously and in an automated way for all P–Es.
According to the WHO, establishment of the temporal
relationship as a causality criterion at the population level
is based on the principle that, ‘‘vaccine exposure must
precede the occurrence of the event’’ [4]. With a few
exceptions, this is mostly the case for events reported in
SRDs, whether causally or just coincidentally related to
vaccination. We recently demonstrated that a temporal
relationship for a vaccine–event (V–E) pair from an SRD
could be quantified by measuring the deviation of its time-
to-onset (TTO) distribution from the overall patterns of
reported TTO of that vaccine with other reported AEs and
of that AE with other vaccines [5–7]. In other words,
temporality could be quantified by measuring the unex-
pectedness of the reported TTO distribution, just as the
strength of association is quantified by measuring how
unexpected the number of reports is for a given V–E pair.
This allowed the development of a new generation of
DMAs able to screen SRDs to flag P–Es with unexpected
TTO distributions autonomously and automatically, with-
out prior medical insight or other data sources.
As stressed in the original proof-of-concept study [5],
the two types of DMAs—TTO and disproportionality
(strength of association)—are complementary theoretically
and in their limitations. The TTO DMA is based on TTO
data, which are neglected by the disproportionality DMA
and recognised to be an important criterion to assess pos-
sible causality during medical evaluation of individual case
reports. On the other hand, TTO DMA can only be per-
formed on the subset of spontaneous reports presenting
TTO values within the window of interest. It excludes
spontaneous reports for which TTO information is missing
or occurs after the predefined time window. Consequently,
TTO DMAs may miss the detection of P–E pairs that have
only a small number of reports with available TTO infor-
mation. Disproportionality DMAs require adjustment to
account for different reporting rates between demographic
or secular strata, but can be performed on uncommon or
long-term AEs.
The use of TTO DMAs raises the practical problem of
quantitative signals that can be generated by either unex-
pected numbers of reports or unexpected TTO distributions.
The flagging of P–E pairs as quantitative signals only when
they are detected as both disproportionate and temporal
signals would result in a signal detection system with lower
sensitivity and higher specificity than either individual
method alone. Knowing that we would systematically lose
the ability to detect uncommon and long-term events, this
option is not viable for a signal detection system. On the
other hand, flagging P–E pairs that are unexpected either in
terms of number of reports or in TTO distribution would
result in a signal detection system with low specificity and
high sensitivity [6]. Consequently, further methodological
research was needed to build a signal detection algorithm
that could account for two, and potentially more, quantified
causality criteria at the population level.
The logistic regression framework was selected and
analysed for its potential to combine multiple factors, and
because previous papers have demonstrated the usage of
logistic regression to weight causality criteria at the indi-
vidual level to model medical expert judgement [8, 9].
Here, we illustrate how logistic regression can be used
to model the probability of a V–E pair being an ARFI,
meaning an AE causally related to immunization, using
disproportionality and unexpectedness of the TTO distri-
bution as predictive variables and the presence of events in
the global product information (GPI) as a predicted
dependent variable. The estimated parameters of the
logistic regression provide the weight of each causality
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criterion to define the probability of being an ARFI [10],
using the current knowledge of the V–Es already recog-
nized as being a safety concern, a piece of information
neglected by both disproportionality and TTO methods.
We use this approach for the two causality criteria at the
population level that can currently be automatically and
autonomously assessed with DMAs from the SRD without
prior medical knowledge.
2 Methods
2.1 The Proportional Reporting Ratio
We selected the PRR [1, 11] for the disproportionality
measure as we highlighted that measures based on the
relative reporting ratio, like the EBGM or IC, are biased
downwards when used on the GSK Vaccines SRD [12].
The PRR is calculated based on a 2 9 2 table, as in
Table 1:
The PRR can be expressed as
PRR ¼ A=ðA þ BÞ
C=ðC þ DÞ
¼ A  ðC þ DÞ
C  ðA þ BÞ
where A, B, C, and D are defined in Table 1. A 95 %









To account for demographic and secular differences
between vaccinated populations, the PRR was stratified by
sex, age, region, and year by using a Mantel–Haenszel
measure of effect [13].
We considered the stratified PRR estimate (PRRE) to
summarize the strength of association, and its 95 % lower
confidence limit (PRRLL) to account for measure variability,
as both measures are often used in DMA based on PRR [14].
2.2 Time-to-Onset Signal Detection
TTO signal detection is a non-parametric DMA for
detecting V–Es with a TTO distribution that is significantly
different from:
– the TTO distribution of the same vaccine with the other
reported events (‘between events’ test)
And
– the TTO distribution of the same event reported after
administration of other vaccines (‘between vaccines’
test)
at a given significance alpha level and within a given
time window [5]. The two-sample Kolmogorov–Smirnov
(KS) test statistic is sensitive to differences in the distri-
bution from which the two samples were drawn, such as
differences in location, dispersion, or skewness.
Here, we use the two p values generated by the ‘between
events’ and ‘between vaccines’ KS tests to summarize the
unexpectedness of TTO data over the 60-day period after
vaccination. The time window of 60 days was previously
associated with high performance in terms of positive pre-
dictive value [6].
The algorithm identifies an unexpected TTO distribution
for a V–E through detection of TTO distributions that
deviate from the overall reported TTO distributions for
other reported events with the vaccine of interest and for the
event of interest with other vaccines. The assumption that
underpins this approach is that most reported V–E pairs are
not causally related, so that the overall TTO distributions
are dominated by reporting biases and noise [7]. This
assumption that most reported V–E pairs are not causally
related also underpins the disproportionality approach and,
if violated, generates the so-called masking effect [15, 16].
2.3 Data Selection
For practicality reasons, the calculation of PRR estimates
and KS p values was restricted to eight vaccines: RotarixTM,
EngerixTM, CervarixTM, FluarixTM, InfanrixTM, InfanrixTM
Hib, HavrixTM, and TwinrixTM. These vaccines together
represented more than half of the vaccine spontaneous
reports in the SRD at the data lock point date of 1 February
2010 and covered a diverse range of vaccine characteristics.
They were thus considered representative of the entire SRD
at GSK vaccines (Tables 2, 3). The entire SRD was used to
compute the PRR and KS p values for these eight vaccines.
2.4 The Dependent Variable
The dependent variable (‘ARFI’) was based on the safety
information from the GPI of each vaccine.
For each V–E, the Medical Dictionary for Regulatory
Activities (MedDRA)1 Preferred Terms corresponding to a
medical term listed in the GPI for that vaccine were assigned





Reports with the vaccine of
interest
A B
All other reports C D
1 Medical Dictionary for Regulatory Activities is a clinically
validated international medical terminology used by regulatory
authorities and the regulated biopharmaceutical industry throughout
the entire regulatory process, from pre-marketing to post-marketing
activities, and for data entry, retrieval, evaluation, and presentation.
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the value 1 and the others the value 0. The list of events in the
GPI is considered as a proxy of the list of events causally
related to the vaccine. Indeed, medical terms in the GPI are
generated from either clinical or post-marketing experience.
For data obtained from randomized clinical trials, a signif-
icant excess of cases in the vaccine group compared with a
control can be causally attributed to the vaccine at a given
significance level due to the properties of randomized clin-
ical trials. Post-marketing data may be generated from a
variety of settings, such as pharmaco-epidemiological
studies, electronic health records, and spontaneous reports;
when there is no equivalent of a randomized study, potential
signals may be highly biased and are consequently usually
subject to evaluation based on causality criteria at the pop-
ulation and individual levels [4] before being included in the
GPI. However, not all medical terms followed this process
before being included in the GPI. In addition, listed medical
terms had to be mapped to MedDRA preferred terms for
consistency with spontaneous report data, which are coded
using the MedDRA dictionary. Consequently, the ARFIs
used could be considered as mainly, if not completely, based
on causality assessments.
2.5 Logistic Regression Models
Logistic regression models the relationship between a
dependent binary variable (the ‘ARFI’ in this case) and
predictive variables. For any V–E pair, an estimated
probability of being an ARFI can be derived based on the
estimated model parameters.
Three different models, characterized by different
choices of predictive variables, have been studied:
Model 1 Using disproportionality information only
logit ARFI 1ð Þð Þ ¼ a1 þ b11PRRE þ b12PRRLL:
The logistic regression modelled the probability of a V–
E being an ARFI based on the disproportionality measure:
the stratified PRR and its 95 % lower limit.
These two predictive variables may have missing val-
ues, for example in the case of a vaccine causing a rare
event, which would then be likely to be reported solely
after the vaccine of interest and never with other vaccines.
As missing values cannot be handled as such by the logistic
regression model, it was important to categorize the PRRE
and its PRRLL. The two variables were thus categorized as
follows2: ‘N/A’; ‘[0, 0.8]’; ‘]0.8, 1.2]’; ‘]1.2, 2]’; ‘]2, 5]’;
‘]5, 10]’; ‘]10, 100]’; ‘100?’.
Model 2 Using unexpectedness of the TTO distribution
only
logit ARFI 1ð Þð Þ ¼ a2 þ b21KSBE þ b22KSBV:
The logistic regression modelled the probability of a V–
E being an ARFI based on the unexpectedness of the TTO
distribution, summarized by the p value of the ‘between
events’ (KSBE) and ‘between vaccines’ (KSBV) KS tests.
The p values KSBE and KSBV were categorized as fol-
lows: ‘N/A’; ‘0’; ‘[Min, Q1[’; ‘[Q1, Median[’; ‘[Median,
Q3[’; ‘[Q3, 0.01]’; ‘]0.01,1]’, where Min, Q1, Median, and
Q3 correspond to the minimum, first quartile, median, and
third quartile observed in the interval ]0, 0.01] for the
p values KSBE and KSBV, respectively. This dynamic cat-
egorization should ensure interpretability and that each
category contains a sufficient number of observations.
Model 3 Using both the disproportionality and the
unexpectedness of the TTO distribution.
Table 2 Description of the therapeutic indication of the vaccines under study
Vaccine Therapeutic indication (extracted from http://www.medicines.org.uk/emc on 14 August 2014)
EngerixTM Active immunization against hepatitis B virus infection caused by all
known subtypes in non-immune subjects
HavrixTM (adult and pediatric) Active immunization against infections caused by hepatitis A virus
CervarixTM Vaccine for use from the age of 9 years for the prevention of premalignant
genital (cervical, vulvar, and vaginal) lesions and cervical cancer causally
related to certain oncogenic human papillomavirus types
InfanrixTM Vaccine indicated for booster vaccination against diphtheria, tetanus, pertussis,
and poliomyelitis diseases in individuals from 16 months to 13 years of age
inclusive who have previously received primary immunization series against these diseases
InfanrixTM Hib Active immunization against diphtheria, tetanus, pertussis, poliomyelitis
and Haemophilus influenzae type b disease from the age of 2 months
RotarixTM Active immunization of infants aged 6–24 weeks for prevention of
gastroenteritis due to rotavirus infection
FluarixTM Prophylaxis of influenza, especially those who run an increased risk of
associated complications. FluarixTM is indicated in adults and children from 6 months of age
TwinrixTM (adult and pediatric) Indicated for individuals who are at risk of both hepatitis A and hepatitis B infection
2 [A,B] refers to an interval between A and B, both values included in
the interval whereas ]A,B,[ refers to an interval between A and B,
both values excluded.
1050 L. Van Holle, V. Bauchau
The logistic regression modelled the probability of a V–
E being an ARFI based on the disproportionality measure
and the unexpectedness of the TTO distribution.
logit ARFI 1ð Þð Þ ¼ a3 þ b31PRRE þ b32PRRLL þ b33KSBE
þ b34KSBV
with the same categorization as for model 1 and 2.
2.6 Measures of Performance
The performance of a logistic regression can be summa-
rized by the following characteristics:
Model fit statistics A global test (Wald test) measures
how likely it is that the group of predictive variables
could be of no use in predicting the value of the
dependent variable (‘ARFI’ here). The more unlikely
(small p values), the better the model fits the data [17].
Discrimination The concordance statistic (also known as
C statistic or area under the curve) [18] measures the
probability that a random listed V–E pair has a higher
probability than a random non-listed V–E pair. The
closer to 1, the better the model discriminates.
Calibration This refers to the agreement between the
observed and predicted outcome for the dependent
variable (‘ARFI’ here). The widely used Hosmer–
Lemeshow test [19] tests the null hypothesis that there
is no difference between the observed and predicted
values of the response variable. The more unlikely
(small p values), the worse the calibration.
Steyerberg [20] showed that bootstrap resulted in the
most accurate estimate of model performance, providing a
bias close to zero. Bootstrapping replicates the process of
sample generation from an underlying population, of the
same size as the original data set, by drawing samples with
replacement from the original data set. We consequently
took 100 bootstrap repetitions of the entire GSK Vaccines
SRD and, for each one, performed the KS tests, calculated
the PRR, and ran the three logistic regression models
described above. For each bootstrap repetition and each
logistic regression, we measured the different performance
criteria of the logistic regression model applied to the
subset of eight vaccines described above.
The performance of each of these models was described
graphically with box plots showing the distribution of the
median and first and third quartile values (indicated by the
middle, top, and bottom lines of the box, respectively). The
interquartile range, containing the middle 50 % of the data,
is thus represented by the vertical length of the box, whilst
the range of the data is the vertical distance between the
smallest and largest values, including or excluding outliers.
The impact of the predictive variables categories on the
estimated probability values was evaluated. The estimated
probability distribution was also compared between the
sources of the data included in the GPI (clinical develop-
ment or post-marketing experience).
The results and figures were produced using SAS9.2.
The following procedures were used: PROC NPAR1WAY
for the calculation of the two-sample KS test p values and
PROC LOGISTIC for the logistic regression.
3 Results
The original dataset contained 9474 V–Es to be modelled
for their probability of being an ARFI, using the three
logistic regression models based on data from the eight
vaccines under study; 803 (8.5 %) were considered as
ARFIs based on the safety information from the GPI. Over
the 100 bootstrap samples, there were an average of 7,831
different V–Es, of which 9.2 % on average were consid-
ered as ARFIs.
3.1 Model Fit Statistics
The global Wald test showed that the three logistic models
were highly significant. The two most significant models
were model 2 (using only the KS test p values) and model 3
(using the KS test p values and the PRR), followed by
model 1 using only the PRR (Fig. 1).
Table 3 Characteristics of spontaneous reports in the GlaxoSmithKline Vaccines spontaneous report database, by vaccine










Engerix TM 31.0 (18.0, 43.0) 64.2 1999 (1993, 2005) 34,347 (23.4 %) 92
HavrixTM 23.0 (11.0, 40.0) 57.8 2004 (1998, 2007) 9,066 (6.2 %) 58
CervarixTM 15.0 (12.0, 17.0) 99.5 2009 (2008, 2009) 3,437 (2.3 %) 63
InfanrixTM 5.0 (1.5, 10.0) 45.5 2006 (2003, 2007) 9,732 (6.6 %) 59
InfanrixTM Hib 1.5 (0.8, 1.9) 42.5 2002 (1999, 2003) 1,027 (0.7 %) 21
RotarixTM 0.3 (0.2, 0.6) 46.3 2008 (2007, 2009) 2,800 (1.9 %) 73
FluarixTM 41.0 (19.0, 60.0) 60.0 2005 (2002, 2007) 6,864 (4.7 %) 69
TwinrixTM 31.0 (19.0, 45.0) 57.6 2006 (2003, 2008) 9,836 (6.7 %) 51
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For model 1, both the PRRE and the PRRLL were highly
significant predictive variables at similar alpha levels. For
model 2, a considerable difference in significance was high-
lighted between KSBV (highly significant) and KSBE (not
significant at alpha level = 0.01) predictive variables. For
model 3, KSBV was the most significant predictive variable,
followed by the PRRE. The PRRLL factor was borderline, with
a significance level of 0.01; the KSBE factor was not significant.
3.2 Discrimination
Model 3 discriminates between the GPI-listed and unlisted
V–Es better than do models 1 and 2 (Fig. 2).
3.3 Calibration
The distribution of the p values for the Hosmer–Lemeshow
test shows that the null hypothesis (no difference between
observed and predicted values) was not rejected at alpha
level 0.01 (represented by a horizontal line across the
graph) for any bootstrap samples used for logistic regres-
sion models 2 and 3 (Fig. 3). However, the null hypothesis
was rejected for 61 of 100 bootstrap samples for model 1.
This suggests that the logistic regression model was well
calibrated when the p values of the KS tests were used as
predictive variables (as in models 2 and 3) but not when
only the stratified PRR and its lower limit were used as
predictive variables (as in model 1).
3.4 Distribution of the Estimated Probability
Figure 4 shows the monotonic relationship between the
p value KSBV and the estimated probability of a V–E being
an ARFI by the model 3: the lower the p value, the higher
the estimated probability. V–E with very low KSBV p val-
ues (0 or in the first quartile of values in the interval ]0,
0.01]) have an estimated probability far above the average
percentage of listed V–Es. For example, V–Es presenting a
null KSBV p value have a median probability around 70 %
(Fig. 4—upper left panel).
The KSBE p value does not show such a monotonic
relationship with the estimated probability. The category
with the highest median estimated probability has an esti-
mated probability around 20 % only (Fig. 4—upper right
panel).
The relationship between the PRR estimate (lower limit)
and the estimated probability is nonlinear, with a local
maximum in the median estimated probability for the ‘]0.8,
1.2]’ (‘]0.8, 1.2]’) category followed by a local minimum
for the ‘]10, 100]’ (‘]0, 0.8]’) category.
The median estimated probability of listed V–Es was the
same whatever the source: clinical development or post-
marketing (Fig. 5). However, the mean estimated
Fig. 1 Wald test p value distribution for the test of the null
hypothesis that beta = 0 for the logistic regression models 1, 2, and 3
Fig. 2 Area under the receiver operating curve (C statistic) distri-
bution for the three logistic regression models
Fig. 3 Hosmer–Lemeshow test p value distribution for the three
logistic regression models
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probability was higher for ARFIs detected at the clinical
level. This could be because some of these ARFIs may
present a very distinctive pattern in terms of dispropor-
tionality and TTO distribution. Regardless of the data
source, the estimated probability was higher for ARFIs
than for the not listed events.
As an example, model 3 gave the highest probability of
being an ARFI for the ten V–E pairs shown in Table 4.
None of these V–E pairs would have been detected by
the stratified PRR when using a threshold of two on the
95 % lower limit, except for the pair RotarixTM–Diarrhoea.
However, a TTO signal would have been generated for all
of them, except for the pair TwinrixTM–Fatigue, using a
threshold of 0.01 for the p value of both KS tests.
Model 1, which uses only disproportionality informa-
tion, estimates a higher probability (36 %) for V–Es having
PRRE = PRRLL = ‘]0.8,1.2]’ because it is within this range
Fig. 4 Distribution of probability estimated by model 3 for each category of the different parameters: a PBV, b PBE, c PRRLL, and d PRRE. The
horizontal line represents the average percentage of vaccine–event pairs listed in the global product information. BE between events, BV between
vaccines, E estimate, LL lower limit, PRR proportional reporting ratio
Fig. 5 Distribution of the estimated probability according to the
source of data having led to some events to be listed in the global
product information
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of values that the observed frequency of known safety
issues was observed. Models 2 and 3 estimate a higher
probability for V–Es with small p values for the KS tests,
and model 3 fluctuates around these probabilities to take
into account the disproportionality information. When
PRRE = PRRLL = ‘]0.8,1.2]’, model 3 estimates higher
probabilities than does model 2.
4 Discussion
Our analyses have shown that the logistic regression can be
used to predict ARFI based on the combination of several
predictive causality criteria at the population level. Among
the combinations tested, the logistic regression based both
on KS p values and on PRR provided the best model in
terms of fit, calibration, and discrimination. The logistic
regression model based on KS p values only (model 2)
provided similar performance results in terms of fit and
calibration but lower performance in terms of discrimina-
tion. The logistic regression model based solely on PRR
(model 1) gave the poorest performance for all measures.
In model 1, the disproportionality information summa-
rized by the PRR estimate and its 95 % lower limit poorly
predicted the presence of AEs in the GPI for the eight
vaccines under study. The unexpectedness of a TTO dis-
tribution, used in model 2 and 3, was a better predictor of
the presence of AEs in the GPI than the disproportionality
information used in model 1.
Taking the GPI as a proxy of the list of events causally
associated with the vaccines, we can conclude that tem-
porality seems to be a stronger predictor of causality than
the strength of association for the eight vaccines under
study, at least when temporality and strength of association
are estimated in the context of spontaneous report data.
This highlights the importance of using this quantified and
objective temporality criterion for signal detection in the
SRD. More specifically, the more confidently one can
reject, for a specific event, the null hypothesis of a common
TTO distribution between the vaccine of interest and the
other vaccines (KSBV), the higher the estimated probability
of a causal association between that event and the vaccine
of interest. On the other hand, the p value of the KSBE was
evaluated by both models 2 and 3 as not being a significant
predictive factor of causality, at least when used with
KSBV. The diverse categories of AEs may generate dif-
ferences in the reported TTO distribution independently
from causal association between the vaccine and event.
Logistic regression has several advantages for improv-
ing quantitative signal detection. First, it uses current
knowledge of the safety profile of the vaccines under post-
marketing pharmacovigilance for attributing weights to the
different measures of unexpectedness, in terms of number
of spontaneous reports and TTO distribution. The model
can be calibrated on the actual SRD of interest and does not
need predefined thresholds extrapolated from other SRDs
with different characteristics or from occasional retro-
spective performance evaluations.
Second, the logistic regression model allows the linear
combination of predictive factors of causality. Causality
assessment is driven by several complementary criteria. The
fact that logistic regression can combine the use of two
causality criteria at the population level (the strength of
association and a more refined notion of temporality) pro-
vides an elegant solution for coping with the complemen-
tarity of these two measures, as previously highlighted [5].
Third, logistic regression solves the dilemma of what
threshold to use for defining disproportionate signals. The
current practice in quantitative signal detection is to treat
disproportionality scores dichotomously: above a given
Table 4 Ten vaccine–event pairs for which model 3 gave the highest probability of being an adverse reaction following immunization






EngerixTM: Myalgia Yes ]0.8, 1.2] ]0.8, 1.2] [Min, Q1[ 0 36 84 93
InfanrixTM: Pyrexia Yes [0, 0.8] [0, 0.8] [Min, Q1[ 0 9 84 86
RotarixTM: Diarrhoea Yes ]10, 100] ]10, 100] [Min, Q1[ [Min, Q1[ 16 86 84
EngerixTM: Pruritus Yes ]0.8, 1.2] ]0.8, 1.2] 0 [Min, Q1[ 36 69 83
EngerixTM: Vomiting Yes ]0.8, 1.2] ]0.8, 1.2] [Min, Q1[ [Q1, Median[ 36 70 83
EngerixTM: Abdominal pain Yes ]1.2, 2] ]0.8, 1.2] [Q1, Median[ [Min, Q1[ 24 74 82
TwinrixTM: Fatigue Yes ]0.8, 1.2] ]0.8, 1.2] [0.01 [Min, Q1[ 36 67 82
EngerixTM: Arthralgia Yes ]0.8, 1.2] ]0.8, 1.2] 0 0 36 65 82
HavrixTM: Headache Yes ]0.8, 1.2] [0, 0.8] [Median, Q3[ 0 12 77 81
CervarixTM: Pyrexia Yes ]0.8, 1.2] [0, 0.8] [Median, Q3[ 0 12 77 81
BE between events, BV between vaccines, E estimate, KS Kolmogorov–Smirnov, LL lower limit, Prob estimated probability, PRR proportional
reporting ratio
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threshold there is a quantitative signal and below it there is
no signal. We previously showed that published recom-
mendations on the use of thresholds may not be optimal [12]
depending on the SRD characteristics. The determination of
the ‘ideal’ threshold is complex and crucial in terms of
signal detection performance. By using categorized values
of the different measures of unexpectedness, we overcome
the uncertainty surrounding the ‘best’ threshold to use.
Indeed, the logistic regression model automatically attri-
butes higher weights to the categories with the highest
predictive value, based on the current knowledge of the
safety profile. It reduces the dependence to the choice of a
unique threshold (even if they are still dependent on our
choices of categories). Some events are solely reported after
a given immunization, not because they are caused by the
vaccination, but sometimes because the report is about a
lack of efficacy of the vaccine. For example, the AEs
‘Rotavirus infection’ or ‘Rotavirus test positive’ are unli-
kely to be spontaneously reported after any vaccination
other than RotarixTM. Consequently, these two events are
characterized by very high values of PRRLL. They actually
fall under the category ‘]10, 100]’. Depending on how
frequently an event listed in the GPI was characterized by a
PRRLL in the category ‘]10, 100]’, the logistic regression
weights this category for predicting ARFIs.
Fourth, logistic regression based on strength of associ-
ation and temporality can provide a score reflecting the
probability of a V–E being an ARFI. This is an intuitive
score for physicians and other non-statisticians. It can be
used directly as a signal detection algorithm: V–Es flagged
with a high probability of being an ARFI (based on
strength of association and temporality) and not yet in the
GPI may present the highest probability of a causal asso-
ciation between the vaccine and the event or at least share
characteristics of events already listed in the GPI. How-
ever, using a logistic regression model directly as a signal
detection algorithm brings challenges that will need careful
prospective evaluation. Indeed, including more causality
criteria in the logistic regression lowered our ability to
detect signals when the KSBV was missing. Indeed, when
KSBV is missing, the estimated probability based on the
other predictive variables (KSBE, PRRE, and PRRLL) will
always be low, as these variables are poor predictors. The
inclusion of several causality criteria in a signal detection
system partially replicates, at an aggregate level, the pro-
cess of signal evaluation where insufficient information
may prevent a conclusion from being drawn.
A hidden assumption behind our logistic regression
model is that the safety profile of the vaccine is for the
most part known and summarized in the GPI given the pre-
marketing data from clinical trials and parallel methods for
detecting signals including literature reviews, post-autho-
rization safety studies, and medical reviewing. Otherwise,
the logistic regression would be fitted based on too high a
proportion of V–Es being misclassified as not causally
associated, which could reduce the model performance for
detecting ARFIs. Furthermore, defining the dependent
variable as the presence of the event in the GPI makes the
‘ARFI’ a time-evolving dependent variable. A dependent
variable reflecting live changes in the GPI could generate
instability in the estimation of the parameter, leading to
instability in the estimated probability of V–Es being
ARFIs. Additional prospective research should be con-
ducted to monitor the stability of the predicted probabilities
over time. The other assumption underlying these logistic
regression models is that the measures of unexpectedness
that are most strongly associated with known safety prob-
lems are those that will also allow us to detect as yet
unknown safety problems.
Previous observations [6] suggest that the detection of
signals based on unexpected TTO distributions requires a
larger number of case reports than the detection of signals
based on disproportionate reporting, since the cases with
missing TTO information cannot be used by KSBV and
KSBE. Consequently, the use of logistic regression could
delay signal detection, at least for signals that had the
potential to be detected by their disproportionality profile
alone. On the other hand, the use of the aggregate and
weighted information about unexpected TTO distribution
and strength of association may flag new V–Es worth
further evaluation.
Finally, logistic regression offers a framework allowing
the use of several causality criteria along with current
knowledge of the safety profiles under monitoring. Addi-
tional research should be conducted to quantify the other
causality criteria at the population level, beyond ‘strength of
association’ and ‘temporality’. For example, ‘specificity’
could be captured as the percentage of reports for which the
vaccine was the only plausible cause for explaining the AE
post-immunization (or the 95 % binomial lower limit of that
percentage to account for variability). The ‘consistency of
evidence’ causality criteria could be a measure of concor-
dance between what has been measured in the SRD under
monitoring and another source (such as registries or
observational data). If the logistic regression models inte-
grating these additional causality criteria appear to perform
better than the one with temporality and strength of asso-
ciation, only then should we consider incorporating these
new quantified causality criteria.
In this study, the theoretical and practical relevance of
the logistic regression framework was analysed on vaccine
spontaneous report data. However, we envision this
framework to be also applicable to drugs, other SRDs, and
observational electronic healthcare databases. Different
settings may be needed to take into account specificities of
the products and database holders, and the dependent
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variable can be defined differently to facilitate early
detection. We take as reference the recent research paper
from Caster [21], where a shrinkage logistic regression
model was applied on Vigibase spontaneous report data to
model the probability that a drug–event pair is an emergent
safety signal. Instead of using solely the causality factors as
potential predictors of being an emergent safety signal,
they pragmatically used the different aspects of strength of
evidence based on report quality and content. A measure of
the unexpectedness of TTO distribution (originally devel-
oped for vaccine spontaneous reports and not yet assessed
on drug spontaneous reports) was not used by the model
but only a crude estimate of the plausibility of the reported
TTO. The logistic regression framework could easily
integrate this refined notion of temporality and would
automatically weight it relative to the other aspects of
strength of evidence. Indirectly, it would also assess if it is
as good a predictor for drug emerging safety signals as it
was for events listed in the GPI of the GSK vaccines under
study.
5 Conclusion
The logistic regression framework allows the combined use
of two causality criteria—the strength of association
(estimated by a disproportionality measure) and the tem-
porality (estimated by a KS test)—to estimate from spon-
taneous report data the probability that a V–E pair is an
ARFI. Logistic regression optimally weights the causality
criteria and combines them based on their ability to predict
known safety issues. A prospective evaluation of this
method is needed to evaluate its potential added value in
the pharmacovigilance toolkit.
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